In anticipation of possible blood shortages during the current COVID-19 pandemic, DeBaun proposes rapid initiation of administration of low, fixed doses of hydroxyurea for children with sickle cell anemia (SCA) who receive regular prophylactic transfusions for stroke prevention.
No takes yet. Share an insight, caveat, or question.
Michael Rutledge DeBaun (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: